Publication Name	World Journal of Gastroenterology
Manuscript ID	6143
Country	Türkiye

Received	2013-10-04 21:24
Peer-Review Started	2013-10-05 14:37
To Make the First Decision	2013-12-16 17:37
Return for Revision	2013-12-17 19:24
Revised	2013-12-26 04:01
Second Decision	2014-03-05 14:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-03-05 15:11
Articles in Press	2014-05-23 11:32
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-03-22 00:25
Typeset the Manuscript	2014-05-29 18:19
Publish the Manuscript Online	2014-06-16 16:19

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Hepatitis C virus reactivation in cancer patients in the era of targeted therapies
Manuscript Source	Invited Manuscript
All Author List	Ozan Yazici, Mehmet Ali Nahit Şendur and Sercan Aksoy
Funding Agency and Grant Number
Corresponding Author	Sercan Aksoy, MD, Department of Medical Oncology, Hacettepe University Cancer Institute, Hacettepe Mh, Sihhiye Ankara 06100, Turkey. saksoy07@yahoo.com
Key Words	Hepatitis C; Hepatitis C reactivation; Monoclonal antibodies; Cancer; Rituximab
Core Tip	During treatment with targeted therapies, especially with monoclonal antibodies, viral replication is one of the major problems for cancer patients. Especially in high risk patients, such as patients with baseline chronic active hepatitis and cirrhosis, and where there are plans to administer rituximab concomitantly with corticosteroids, it is advised to have close follow-up of hepatitis C virus (HCV) viral load and to perform liver function tests. During alemtuzumab therapy we also advise to follow liver function tests and HCV RNA levels. In the course of imatinib therapy, clinicians should follow liver function alterations. Anti-human epidermal growth factor receptor 2, anti-epidermal growth factor receptor, and immunomodulating therapies can be safely used in HCV positive patients.
Publish Date	2014-06-16 16:19
Citation	Yazici O, Şendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20(22): 6716-6724
URL	http://www.wjgnet.com/1007-9327/full/v20/i22/6716.htm
DOI	10.3748/wjg.v20.i22.6716

Full Article (PDF)	WJG-20-6716.pdf
Full Article (Word)	WJG-20-6716.doc
Manuscript File	6143-Review.docx
Answering Reviewers	6143-Answering reviewers.pdf
Copyright License Agreement	6143-Copyright assignment.pdf
Peer-review Report	6143-Peer review(s).pdf
Scientific Editor Work List	6143-Scientific editor work list.doc